Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/off-label-use-of-rituximab-in-systemic-lupus-erythematosus-a-88RIU0y0dQ
References (72)
-
R. Pepper, M. Griffith, C. Kirwan, J. Levy, D. Taube, C. Pusey, L. Lightstone, T. Cairns (2009)
Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 24 12
-
O. Chan, M. Madaio, M. Shlomchik (1999)
B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity.Journal of immunology, 163 7
-
(Perry ME, Lavelle C, Maguire N, McKinstry Z, Paton D, Murray E, Field M (2020). Scottish use of B cell depletion therapy (rituximab) in connective tissue patients: ‘real life’ experience of the first 40 patients. Scottish Medical Journal (in press))
Perry ME, Lavelle C, Maguire N, McKinstry Z, Paton D, Murray E, Field M (2020). Scottish use of B cell depletion therapy (rituximab) in connective tissue patients: ‘real life’ experience of the first 40 patients. Scottish Medical Journal (in press)Perry ME, Lavelle C, Maguire N, McKinstry Z, Paton D, Murray E, Field M (2020). Scottish use of B cell depletion therapy (rituximab) in connective tissue patients: ‘real life’ experience of the first 40 patients. Scottish Medical Journal (in press), Perry ME, Lavelle C, Maguire N, McKinstry Z, Paton D, Murray E, Field M (2020). Scottish use of B cell depletion therapy (rituximab) in connective tissue patients: ‘real life’ experience of the first 40 patients. Scottish Medical Journal (in press)
-
(SIGN 50: A guideline developer’s handbook. Annex B: Key to evidence statements and grades of recommendations. http://www.sign.ac.uk/guidelines/fulltext/50/annexb.html)
SIGN 50: A guideline developer’s handbook. Annex B: Key to evidence statements and grades of recommendations. http://www.sign.ac.uk/guidelines/fulltext/50/annexb.htmlSIGN 50: A guideline developer’s handbook. Annex B: Key to evidence statements and grades of recommendations. http://www.sign.ac.uk/guidelines/fulltext/50/annexb.html, SIGN 50: A guideline developer’s handbook. Annex B: Key to evidence statements and grades of recommendations. http://www.sign.ac.uk/guidelines/fulltext/50/annexb.html
-
(K. Furie et al (2009) Trial design and baseline characteristics of patients in the randomised double-blind, placebo controlled phase III lupus nephritis assessment with rituximab study (LUNAR). Ann Rheum Dis 2009 (suppl 3): 253.LUNAR Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint. March 2009 23:13. http://www.news-medical.net/news/2009/03/11/46787.aspx. Sourced 24/05/09)
K. Furie et al (2009) Trial design and baseline characteristics of patients in the randomised double-blind, placebo controlled phase III lupus nephritis assessment with rituximab study (LUNAR). Ann Rheum Dis 2009 (suppl 3): 253.LUNAR Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint. March 2009 23:13. http://www.news-medical.net/news/2009/03/11/46787.aspx. Sourced 24/05/09K. Furie et al (2009) Trial design and baseline characteristics of patients in the randomised double-blind, placebo controlled phase III lupus nephritis assessment with rituximab study (LUNAR). Ann Rheum Dis 2009 (suppl 3): 253.LUNAR Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint. March 2009 23:13. http://www.news-medical.net/news/2009/03/11/46787.aspx. Sourced 24/05/09, K. Furie et al (2009) Trial design and baseline characteristics of patients in the randomised double-blind, placebo controlled phase III lupus nephritis assessment with rituximab study (LUNAR). Ann Rheum Dis 2009 (suppl 3): 253.LUNAR Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint. March 2009 23:13. http://www.news-medical.net/news/2009/03/11/46787.aspx. Sourced 24/05/09
-
J. Anolik, J. Barnard, T. Owen, B. Zheng, Sunil Kemshetti, R. Looney, I. Sanz (2007)
Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy.Arthritis and rheumatism, 56 9
-
R. Weide, J. Heymanns, A. Pandorf, H. Köppler (2003)
Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapyLupus, 12
-
Kenneth Smith, R. Jones, S. Burns, D. Jayne (2006)
Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.Arthritis and rheumatism, 54 9
-
N. Danchenko, J. Satia, M. Anthony (2006)
Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burdenLupus, 15
-
M. Tokunaga, K. Fujii, K. Saito, S. Nakayamada, S. Tsujimura, M. Nawata, Yoshiya Tanaka (2005)
Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.Rheumatology, 44 2
-
F. Formiga, I. Moga, M. Pac, F. Mitjavila, A. Rivera, R. Pujol (1999)
High disease activity at baseline does not prevent a remission in patients with systemic lupus erythematosus.Rheumatology, 38 8
-
Interferon activation in human SLE bone marrow inhibits B cell lymphopoiesis. Poster presented at 72nd Annual Scientific Meeting of the American College of Rheumatology -
T. Lu, K. Ng, G. Cambridge, M. Leandro, J. Edwards, M. Ehrenstein, D. Isenberg (2008)
A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.Arthritis and rheumatism, 61 4
-
Catherine Melander, M. Sallée, P. Trolliet, S. Candon, X. Belenfant, E. Daugas, P. Rémy, V. Zarrouk, É. Pillebout, C. Jacquot, J. Boffa, A. Karras, V. Masse, P. Lesavre, C. Elie, I. Brocheriou, B. Knebelmann, L. Noël, F. Fakhouri (2009)
Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome.Clinical journal of the American Society of Nephrology : CJASN, 4 3
-
J. Merrill, R. Burgos-Vargas, R. Westhovens, A. Chalmers, D. D'cruz, D. Wallace, S. Bae, L. Sigal, J. Becker, S. Kelly, K. Raghupathi, Y. Peng, M. Kinaszczuk, P. Nash (2008)
The Efficacy and Safety of Abatacept in SLE: Results of a 12-month Exploratory StudyArthritis & Rheumatism, 58
-
(2008)
Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus: results from the randomized, double-blind phase II/III study EXPLORER -
(2008)
Rituximab (RTX) for refractory and relapsing SLE -
R. Looney, J. Anolik, D. Campbell, R. Felgar, F. Young, L. Arend, J. Sloand, J. Rosenblatt, I. Sanz (2004)
B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.Arthritis and rheumatism, 50 8
-
I. Gunnarsson, B. Sundelin, T. Jónsdóttir, S. Jacobson, E. Henriksson, R. Vollenhoven (2007)
Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.Arthritis and rheumatism, 56 4
-
(Merrill J et al (2008) The efficacy and safety of abatacept in SLE: results of a 12-month exploratory study (Abstract L15). Program and abstracts of the American College of Rheumatology 2008 Annual Scientific Meeting: San Francisco. Oct 2008)
Merrill J et al (2008) The efficacy and safety of abatacept in SLE: results of a 12-month exploratory study (Abstract L15). Program and abstracts of the American College of Rheumatology 2008 Annual Scientific Meeting: San Francisco. Oct 2008Merrill J et al (2008) The efficacy and safety of abatacept in SLE: results of a 12-month exploratory study (Abstract L15). Program and abstracts of the American College of Rheumatology 2008 Annual Scientific Meeting: San Francisco. Oct 2008, Merrill J et al (2008) The efficacy and safety of abatacept in SLE: results of a 12-month exploratory study (Abstract L15). Program and abstracts of the American College of Rheumatology 2008 Annual Scientific Meeting: San Francisco. Oct 2008
-
(2009)
Trial design and baseline characteristics of patients in the randomised double-blind, placebo controlled phase III lupus nephritis assessment with rituximab study (LUNAR) -
F. Lavie, C. Miceli-Richard, M. Ittah, J. Sellam, J. Gottenberg, X. Mariette (2006)
Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF productionAnnals of the Rheumatic Diseases, 66
-
J. Boletis, S. Marinaki, Chryssanthe Skalioti, S. Lionaki, A. Iniotaki, P. Sfikakis (2009)
Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 24 7
-
J. Anolik, D. Campbell, R. Felgar, F. Young, I. Sanz, J. Rosenblatt, R. Looney (2003)
The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosusArthritis & Rheumatism, 48
-
E. Hay, P. Bacon, C. Gordon, D. Isenberg, P. Maddison, M. Snaith, D. Symmons, N. Viner, A. Zoma (1993)
The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus.The Quarterly journal of medicine, 86 7
-
Bimba Hoyer, K. Moser, Anja Hauser, A. Peddinghaus, C. Voigt, D. Eilat, A. Radbruch, F. Hiepe, Rudolf Manz (2004)
Differential antibody recognition of the 349–364aa B-cell epitope of human La/SSB protein and its phosphorylated analogueArthritis Research & Therapy, 6
-
(Barnard J, Palanichamy A, Bauer JW, Anolik JH et al (2008) Interferon activation in human SLE bone marrow inhibits B cell lymphopoiesis. Poster presented at 72nd Annual Scientific Meeting of the American College of Rheumatology; October 24–29, 2008; San Francisco, CA)
Barnard J, Palanichamy A, Bauer JW, Anolik JH et al (2008) Interferon activation in human SLE bone marrow inhibits B cell lymphopoiesis. Poster presented at 72nd Annual Scientific Meeting of the American College of Rheumatology; October 24–29, 2008; San Francisco, CABarnard J, Palanichamy A, Bauer JW, Anolik JH et al (2008) Interferon activation in human SLE bone marrow inhibits B cell lymphopoiesis. Poster presented at 72nd Annual Scientific Meeting of the American College of Rheumatology; October 24–29, 2008; San Francisco, CA, Barnard J, Palanichamy A, Bauer JW, Anolik JH et al (2008) Interferon activation in human SLE bone marrow inhibits B cell lymphopoiesis. Poster presented at 72nd Annual Scientific Meeting of the American College of Rheumatology; October 24–29, 2008; San Francisco, CA
-
C. Bombardier, D. Gladman, M. Urowitz, Dominique Caron, Chih Chang, A. Austin, A. Bell, D. Bloch, Paul Corey, J. Decker, J. Esdaile, J. Fries, E. Ginzler, C. Goldsmith, M. Hochberg, John Jones, Nicole Riche, M. Liang, M. Lockshin, L. Muenz, D. Sackett, P. Schur (1992)
Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.Arthritis and rheumatism, 35 6
-
the Committee on Prognosis Studies in SLE (1992) Derivation of the SLEDAI: a disease activity index for lupus patients -
F. Hernández, C. Medina, R. León, R. Rasco, Regina Bonilla, M. Palma, J. Román (2007)
Utilidad del rituximab en el tratamiento de pacientes con enfermedades sistémicasMedicina Clinica, 128
-
(Genentech, Inc. and Biogen Idec. http://www.news-medical.net/news/2009/03/11/46787.aspx)
Genentech, Inc. and Biogen Idec. http://www.news-medical.net/news/2009/03/11/46787.aspxGenentech, Inc. and Biogen Idec. http://www.news-medical.net/news/2009/03/11/46787.aspx, Genentech, Inc. and Biogen Idec. http://www.news-medical.net/news/2009/03/11/46787.aspx
-
(2001)
KEY TO EVIDENCE STATEMENTS AND GRADES OF RECOMMENDATIONS -
Y. Tamimoto, Takahiko Horiuchi, Hiroshi Tsukamoto, J. Otsuka, H. Mitoma, Y. Kimoto, Hitoshi Nakashima, K. Muta, Y. Abe, Chikako Kiyohara, Akira Ueda, Kohei Nagasawa, Shigeru Yoshizawa, Terufumi Shimoda, Mine Harada (2008)
A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines.Rheumatology, 47 6
-
Wei-qing Huang, Jayashree Sinha, J. Newman, B. Reddy, Lalbachan Budhai, R. Furie, A. Vaishnaw, A. Davidson (2002)
The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus.Arthritis and rheumatism, 46 6
-
M. Karim, P. Alba, M. Cuadrado, I. Abbs, D. D'cruz, M. Khamashta, G. Hughes (2002)
Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents.Rheumatology, 41 8
-
F. Hernández, C. Medina, R. León, R. Rasco, Regina Bonilla, M. Palma, J. Román (2007)
[Rituximab for treatment of patients with systemic autoimmune diseases].Medicina clinica, 128 12
-
A. Mohrbacher (2005)
B cell non-Hodgkin's lymphoma: rituximab safety experienceArthritis Research & Therapy, 7
-
(Sangle SR et al (2007) Rituximab in the treatment of resistant systemic lupus erythematosus: failure of therapy in rapidly progressive crescentic lupus nephritis. Arthritis Rheum 56. ACR/ARHP Abstract 441)
Sangle SR et al (2007) Rituximab in the treatment of resistant systemic lupus erythematosus: failure of therapy in rapidly progressive crescentic lupus nephritis. Arthritis Rheum 56. ACR/ARHP Abstract 441Sangle SR et al (2007) Rituximab in the treatment of resistant systemic lupus erythematosus: failure of therapy in rapidly progressive crescentic lupus nephritis. Arthritis Rheum 56. ACR/ARHP Abstract 441, Sangle SR et al (2007) Rituximab in the treatment of resistant systemic lupus erythematosus: failure of therapy in rapidly progressive crescentic lupus nephritis. Arthritis Rheum 56. ACR/ARHP Abstract 441
-
E. Clark, J. Ledbetter (2005)
How does B cell depletion therapy work, and how can it be improved?Annals of the Rheumatic Diseases, 64
-
John Reynolds, V. Toescu, C. Yee, A. Prabu, D. Situnayake, Caroline Gordon (2009)
Effects of rituximab on resistant SLE disease including lung involvementLupus, 18
-
(2009)
Good safety profile of repeated b cell depletion therapy in patients with refractory systemic lupus erythematosusAnn Rheum Dis, 68
-
(Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG (2008) Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus: results from the randomized, double-blind phase II/III study EXPLORER. Presented at 72nd Annual Scientific Meeting of the American College of Rheumatology; October 24–29, 2008; San Francisco, CA. Abstract L12 )
Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG (2008) Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus: results from the randomized, double-blind phase II/III study EXPLORER. Presented at 72nd Annual Scientific Meeting of the American College of Rheumatology; October 24–29, 2008; San Francisco, CA. Abstract L12Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG (2008) Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus: results from the randomized, double-blind phase II/III study EXPLORER. Presented at 72nd Annual Scientific Meeting of the American College of Rheumatology; October 24–29, 2008; San Francisco, CA. Abstract L12 , Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG (2008) Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus: results from the randomized, double-blind phase II/III study EXPLORER. Presented at 72nd Annual Scientific Meeting of the American College of Rheumatology; October 24–29, 2008; San Francisco, CA. Abstract L12
-
M. Tokunaga, K. Saito, D. Kawabata, Y. Imura, T. Fujii, S. Nakayamada, S. Tsujimura, M. Nawata, S. Iwata, T. Azuma, T. Mimori, Yoshiya Tanaka (2006)
Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous systemAnnals of the Rheumatic Diseases, 66
-
C. Galarza, D. Valencia, G. Tobón, L. Zurita, R. Mantilla, R. Pineda-Tamayo, A. Rojas-Villarraga, J. Rueda, J. Anaya (2008)
Should Rituximab be Considered as the First-Choice Treatment for Severe Autoimmune Rheumatic Diseases?Clinical Reviews in Allergy & Immunology, 34
-
T. Jónsdóttir, I. Gunnarsson, A. Risselada, E. Henriksson, Lars Klareskog, R. Vollenhoven (2007)
Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of responseAnnals of the Rheumatic Diseases, 67
-
H. Bootsma, P. Spronk, G. Boer, P. Limburg, C. Kallenberg, R. Derksen, J. Wolters-Dicke, F. Gmelig‐Meyling, L. Kater, J. Hermans (1995)
Prevention of relapses in systemic lupus erythematosusThe Lancet, 345
-
M. Shahrir, A. Halim, Z. Soehardy, C. Kong (2007)
Clinical experience in using CD20 monoclonal antibody in treating severe systemic lupus erythematosusAplar Journal of Rheumatology, 10
-
(2007)
A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosusMod Rheumatol, 17
-
N. Kasitanon, L. Magder, M. Petri (2006)
Predictors of Survival in Systemic Lupus ErythematosusMedicine, 85
-
F. Martin, A. Chan (2006)
B cell immunobiology in disease: evolving concepts from the clinic.Annual review of immunology, 24
-
A. Grammer, P. Lipsky (2003)
B cell abnormalities in systemic lupus erythematosusArthritis Research & Therapy, 5
-
P. Sfikakis, J. Boletis, S. Lionaki, V. Vigklis, K. Fragiadaki, A. Iniotaki, H. Moutsopoulos (2005)
Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.Arthritis and rheumatism, 52 2
-
J. Anolik, J. Barnard, A. Cappione, A. Pugh-Bernard, R. Felgar, R. Looney, I. Sanz (2004)
Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.Arthritis and rheumatism, 50 11
-
(2007)
Rituximab in the treatment of resistant systemic lupus erythematosus: failure of therapy in rapidly progressive crescentic lupus nephritis -
Qian Gong, Qinglin Ou, Shiming Ye, Wyne Lee, Jennine Cornelius, L. Diehl, W. Lin, Zhilan Hu, Yanmei Lu, Yongmei Chen, Yan Wu, Y. Meng, P. Gribling, Zhonghua Lin, Kathy Nguyen, Thanhvien Tran, Yifan Zhang, H. Rosen, F. Martin, A. Chan (2005)
Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy1The Journal of Immunology, 174
-
(2009)
Rituximab therapy induces durable remissions in patients with refractory systemic lupus erythematosus (SLE)Ann Rheum Dis, 68
-
C. Gordon, G. Bertsias, J. Ioannidis, J. Boletis, S. Bombardieri, R. Cervera, C. Dostál, J. Font, I. Gilboe, F. Houssiau, T. Huizinga, D. Isenberg, C. Kallenberg, M. Khamashta, J. Piette, M. Schneider, J. Smolen, G. Sturfelt, A. Tincani, R. Vollenhoven, D. Boumpas (2008)
EULAR points to consider for conducting clinical trials in systemic lupus erythematosusAnnals of the Rheumatic Diseases, 68
-
J. Gottenberg, L. Guillevin, O. Lambotte, B. Combe, Y. Allanore, A. Cantagrel, C. Larroche, M. Soubrier, L. Bouillet, M. Dougados, O. Fain, D. Farge, X. Kyndt, O. Lortholary, C. Masson, B. Moura, P. Rémy, T. Thomas, D. Wendling, J. Anaya, J. Sibilia, X. Mariette (2004)
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseasesAnnals of the Rheumatic Diseases, 64
-
F. Heidel, D. Lipka, C. Auer, C. Huber, I. Scharrer, G. Hess (2007)
Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemiaThrombosis and Haemostasis, 97
-
(2004)
Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W miceJ Exp Med, 199
-
Yoshiya Tanaka, K. Yamamoto, T. Takeuchi, N. Nishimoto, N. Miyasaka, T. Sumida, Y. Shima, K. Takada, I. Matsumoto, K. Saito, T. Koike (2007)
A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosusModern Rheumatology, 17
-
D. Albert, Jonathan Dunham, Salar Khan, J. Stansberry, S. Kolasinski, Donald Tsai, Sally Pullman-Mooar, F. Barnack, Christopher Striebich, R. Looney, E. Prak, Robert Kimberly, Y. Zhang, Robert Eisenberg (2008)
Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosusAnnals of the Rheumatic Diseases, 67
-
V. Strand, D. Gladman, D. Isenberg, Michelle Petri, J. Smolen, P. Tugwell (2000)
Endpoints: consensus recommendations from OMERACT IVLupus, 9
-
O. Chan, L. Hannum, A. Haberman, M. Madaio, M. Shlomchik (1999)
A Novel Mouse with B Cells but Lacking Serum Antibody Reveals an Antibody-independent Role for B Cells in Murine LupusThe Journal of Experimental Medicine, 189
-
J. Anolik, D. Campbell, R. Felgar, F. Young, I. Sanz, J. Rosenblatt, R. Looney (2003)
The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.Arthritis and rheumatism, 48 2
-
LUNAR Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint -
E. Li, L. Tam, T. Zhu, Martin Li, Catherine Kwok, Tena Li, Ying-Ying Leung, K. Wong, C. Szeto (2009)
Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?Rheumatology, 48 8
-
J. Gillis, M. Dall'era, A. Gross, J. Yazdany, John Davis (2007)
Six refractory lupus patients treated with rituximab: a case series.Arthritis and rheumatism, 57 3
-
M. Vigna-Pérez, B. Hernández-Castro, O. Paredes-Saharopulos, D. Portales-Pérez, L. Baranda, C. Abud-Mendoza, R. González-Amaro (2006)
Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot studyArthritis Research & Therapy, 8
-
(Catapano et al (2008) Rituximab (RTX) for refractory and relapsing SLE. American Society of Nephrology, Renal Week, Nov 4–9 2008, SA-PO2960)
Catapano et al (2008) Rituximab (RTX) for refractory and relapsing SLE. American Society of Nephrology, Renal Week, Nov 4–9 2008, SA-PO2960Catapano et al (2008) Rituximab (RTX) for refractory and relapsing SLE. American Society of Nephrology, Renal Week, Nov 4–9 2008, SA-PO2960, Catapano et al (2008) Rituximab (RTX) for refractory and relapsing SLE. American Society of Nephrology, Renal Week, Nov 4–9 2008, SA-PO2960
-
J. Edwards, L. Szczepański, J. Szechiński, A. Filipowicz-Sosnowska, P. Emery, D. Close, R. Stevens, T. Shaw (2004)
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.The New England journal of medicine, 350 25
-
C. Lindholm, Katharina Börjesson-Asp, Kiandokht Zendjanchi, A. Sundqvist, A. Tarkowski, M. Bokarewa (2008)
Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.The Journal of rheumatology, 35 5
- Publisher
- Springer Journals
- Copyright
- Copyright © 2010 by Clinical Rheumatology
- Subject
- Medicine & Public Health; Rheumatology
- ISSN
- 0770-3198
- eISSN
- 1434-9949
- DOI
- 10.1007/s10067-010-1387-5
- pmid
- 20155295
- Publisher site
- See Article on Publisher Site
Abstract
Considerable interest in the efficacy of rituximab (a monoclonal CD20 antibody) in patients with systemic lupus erythematosus (SLE) has been generated due to its unique mode of action, culminating in a series of randomized and open trials, and case reports. However, this use is off-license and two significant RCTs have reported negative findings, reopening the debate on clinical benefit. This review of the available data suggests that rituximab induces B-cell depletion in 95% of patients, and a significant reduction in disease activity is achieved with a relatively good safety profile in patients with SLE.
Journal
Clinical Rheumatology – Springer Journals
Published: Feb 13, 2010